473 related articles for article (PubMed ID: 9421305)
21. Interference of neutrophil-platelet interaction by YC-1: a cGMP-dependent manner on heterotypic cell-cell interaction.
Liao CH; Cheng JT; Teng CM
Eur J Pharmacol; 2005 Sep; 519(1-2):158-67. PubMed ID: 16112105
[TBL] [Abstract][Full Text] [Related]
22. Endothelium-dependent and -independent vasorelaxation by a theophylline derivative MCPT: roles of cyclic nucleotides, potassium channel opening and phosphodiesterase inhibition.
Lo YC; Tsou HH; Lin RJ; Wu DC; Wu BN; Lin YT; Chen IJ
Life Sci; 2005 Jan; 76(8):931-44. PubMed ID: 15589969
[TBL] [Abstract][Full Text] [Related]
23. Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta.
Linder AE; McCluskey LP; Cole KR; Lanning KM; Webb RC
J Pharmacol Exp Ther; 2005 Jul; 314(1):9-15. PubMed ID: 15778264
[TBL] [Abstract][Full Text] [Related]
24. YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats.
Hsieh GC; O'Neill AB; Moreland RB; Sullivan JP; Brioni JD
Eur J Pharmacol; 2003 Jan; 458(1-2):183-9. PubMed ID: 12498924
[TBL] [Abstract][Full Text] [Related]
25. BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro.
Kalsi JS; Rees RW; Hobbs AJ; Royle M; Kell PD; Ralph DJ; Moncada S; Cellek S
J Urol; 2003 Feb; 169(2):761-6. PubMed ID: 12544359
[TBL] [Abstract][Full Text] [Related]
26. A comparative study of the effects of three guanylyl cyclase inhibitors on the L-type Ca2+ and muscarinic K+ currents in frog cardiac myocytes.
Abi-Gerges N; Hove-Madsen L; Fischmeister R; Méry PF
Br J Pharmacol; 1997 Aug; 121(7):1369-77. PubMed ID: 9257916
[TBL] [Abstract][Full Text] [Related]
27. The nitric oxide donors, SNAP and DEA/NO, exert a negative inotropic effect in rat cardiomyocytes which is independent of cyclic GMP elevation.
Sandirasegarane L; Diamond J
J Mol Cell Cardiol; 1999 Apr; 31(4):799-808. PubMed ID: 10329207
[TBL] [Abstract][Full Text] [Related]
28. Involvement of cyclic nucleotide-dependent protein kinases in cyclic AMP-mediated vasorelaxation.
Eckly-Michel A; Martin V; Lugnier C
Br J Pharmacol; 1997 Sep; 122(1):158-64. PubMed ID: 9298542
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of extracellular Ca(2+) entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils.
Wang JP; Chang LC; Huang LJ; Kuo SC
Biochem Pharmacol; 2001 Sep; 62(6):679-84. PubMed ID: 11551512
[TBL] [Abstract][Full Text] [Related]
30. Activation of soluble guanylyl cyclase inhibits estradiol production and cyclic AMP accumulation from cultured rat granulosa cells.
Tafoya MA; Chen JY; Stewart RL; Lapolt PS
Fertil Steril; 2004 Oct; 82 Suppl 3():1154-9. PubMed ID: 15474089
[TBL] [Abstract][Full Text] [Related]
31. BAY 41-2272, a potent activator of soluble guanylyl cyclase, stimulates calcium elevation and calcium-activated potassium current in pituitary GH cells.
Liu YC; Wu SN
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1078-87. PubMed ID: 16445574
[TBL] [Abstract][Full Text] [Related]
32. Role of sodium-calcium exchange and effects of calcium entry blockers on endothelial-mediated responses in rat isolated aorta.
Schoeffter P; Miller RC
Mol Pharmacol; 1986 Jul; 30(1):53-7. PubMed ID: 3014308
[TBL] [Abstract][Full Text] [Related]
33. Comparative relaxant effects of YC-1 and DETA/NO on spontaneous contractions and the levels of cGMP of isolated pregnant rat myometrium.
Demirkoprulu N; Cetin M; Bagcivan I; Kaya T; Soydan AS; Karadas B; Cetin A
Eur J Pharmacol; 2005 Jul; 517(3):240-5. PubMed ID: 15985262
[TBL] [Abstract][Full Text] [Related]
34. Human trabecular meshwork cell volume decrease by NO-independent soluble guanylate cyclase activators YC-1 and BAY-58-2667 involves the BKCa ion channel.
Dismuke WM; Sharif NA; Ellis DZ
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3353-9. PubMed ID: 19234350
[TBL] [Abstract][Full Text] [Related]
35. Nifedipine enhances cGMP production through the activation of soluble guanylyl cyclase in rat ventricular papillary muscle.
Seya K; Furukawa K; Yoshida K; Narita R; Motomura S
J Pharm Pharmacol; 2005 Apr; 57(4):511-4. PubMed ID: 15831213
[TBL] [Abstract][Full Text] [Related]
36. Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect.
Böhm M; Brückner R; Hackbarth I; Haubitz B; Linhart R; Meyer W; Schmidt B; Schmitz W; Scholz H
J Pharmacol Exp Ther; 1984 Aug; 230(2):483-92. PubMed ID: 6086891
[TBL] [Abstract][Full Text] [Related]
37. Effects of colforsin, trequinsin and isoprenaline on norepinephrine-induced contractions and cyclic nucleotide levels of isolated vascular tissue.
Linz W; Wiemer G; Schölkens BA
Arzneimittelforschung; 1988 Feb; 38(2):240-3. PubMed ID: 2835960
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole.
Chien WL; Liang KC; Teng CM; Kuo SC; Lee FY; Fu WM
Mol Pharmacol; 2003 Jun; 63(6):1322-8. PubMed ID: 12761342
[TBL] [Abstract][Full Text] [Related]
39. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
40. A-350619: a novel activator of soluble guanylyl cyclase.
Miller LN; Nakane M; Hsieh GC; Chang R; Kolasa T; Moreland RB; Brioni JD
Life Sci; 2003 Jan; 72(9):1015-25. PubMed ID: 12495780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
